BR112016003293A2 - anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos - Google Patents
anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicosInfo
- Publication number
- BR112016003293A2 BR112016003293A2 BR112016003293A BR112016003293A BR112016003293A2 BR 112016003293 A2 BR112016003293 A2 BR 112016003293A2 BR 112016003293 A BR112016003293 A BR 112016003293A BR 112016003293 A BR112016003293 A BR 112016003293A BR 112016003293 A2 BR112016003293 A2 BR 112016003293A2
- Authority
- BR
- Brazil
- Prior art keywords
- rheumatoid arthritis
- neutralizing antibodies
- treatment
- csf neutralizing
- analgesics
- Prior art date
Links
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 title abstract 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 title abstract 3
- 230000003472 neutralizing effect Effects 0.000 title abstract 3
- 206010039073 rheumatoid arthritis Diseases 0.000 title abstract 3
- 229940035676 analgesics Drugs 0.000 title 1
- 239000000730 antalgic agent Substances 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente invenção refere-se a anticorpos neutralizantes de gm-csf e composições compreendendo os mesmos para uso no tratamento de desordens inflamatórias, tais como artrite reumatoide de acordo com regime de dosagem específico. a invenção refere-se também a anticorpos neutralizantes de gm-csf e composições compreendendo os mesmos para uso no tratamento da dor, por exemplo, dor experimentada nas desordens inflamatórias, tais como artrite reumatoide, de acordo com o regime de dosagem específica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361871900P | 2013-08-30 | 2013-08-30 | |
US201361871904P | 2013-08-30 | 2013-08-30 | |
PCT/EP2014/068489 WO2015028657A1 (en) | 2013-08-30 | 2014-09-01 | Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016003293A2 true BR112016003293A2 (pt) | 2017-11-21 |
BR112016003293A8 BR112016003293A8 (pt) | 2022-08-16 |
Family
ID=51454704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016003293A BR112016003293A8 (pt) | 2013-08-30 | 2014-09-01 | Anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos |
Country Status (12)
Country | Link |
---|---|
US (2) | US10745475B2 (pt) |
EP (2) | EP3889178A1 (pt) |
JP (4) | JP2016536327A (pt) |
KR (3) | KR20220045064A (pt) |
CN (2) | CN118178647A (pt) |
AU (3) | AU2014314053C1 (pt) |
BR (1) | BR112016003293A8 (pt) |
CA (1) | CA2922251C (pt) |
ES (1) | ES2860480T3 (pt) |
MX (2) | MX2016002177A (pt) |
RU (1) | RU2714919C2 (pt) |
WO (1) | WO2015028657A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060022659A (ko) | 2003-05-15 | 2006-03-10 | 디엠아이 바이오사이언시스, 인크 | T-세포 매개성 질환의 치료 방법 |
US8980834B2 (en) | 2011-10-10 | 2015-03-17 | Ampio Pharmaceuticals, Inc. | Treatment of degenerative joint disease |
RU2020136589A (ru) | 2014-08-18 | 2020-12-24 | Ампио Фармасьютикалз, Инк. | Лечение дегенеративных заболеваний суставов |
EP3310375A4 (en) * | 2015-06-22 | 2019-02-20 | Ampio Pharmaceuticals, Inc. | USE OF LOW MOLECULAR WEIGHT HUMAN SERUM ALBUMIN FRACTIONS FOR TREATING DISEASES |
UA126565C2 (uk) | 2016-09-19 | 2022-11-02 | Ай-Маб Байофарма (Ханчжоу) Ко., Лтд. | Антитіло до гм-ксф |
CN107840885B (zh) * | 2016-09-19 | 2020-11-10 | 天境生物科技(上海)有限公司 | Gm-csf抗体及其用途 |
CA3051865C (en) | 2017-02-01 | 2023-01-17 | Yale University | Treatment of diuretic resistance |
SG11202006157VA (en) * | 2018-01-05 | 2020-07-29 | Corvidia Therapeutics Inc | Methods for treating il-6 mediated inflammation without immunosuppression |
WO2019178379A2 (en) * | 2018-03-14 | 2019-09-19 | Indiana University Research And Technology Corporation | Precision medicine for pain: diagnostic biomarkers, pharmacogenomics, and repurposed drugs |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2916711A1 (de) | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blutgerinnungsfaktoren und verfahren zu ihrer herstellung |
US4783441A (en) | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
JPS59147297A (ja) | 1983-02-10 | 1984-08-23 | 株式会社日立製作所 | 原子炉圧力容器の耐震構造 |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE3583880D1 (de) | 1984-04-09 | 1991-10-02 | Takeda Chemical Industries Ltd | Stabile interleukin-2-zusammensetzung. |
GB8624899D0 (en) | 1986-10-17 | 1986-11-19 | Sandoz Ltd | Monoclonal antibodies |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5070013A (en) | 1988-05-31 | 1991-12-03 | Schering Corporation | Immunochemical assay for human granulocyte-macrophage colony stimulating factor |
GB8903593D0 (en) | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
US5747032A (en) | 1990-08-10 | 1998-05-05 | Amrad Corporation Limited | Monoclonal antibody to human granulocyte macrophage colony stimulating factor |
CA2060741A1 (en) | 1991-02-11 | 1992-08-12 | Robert S. Greenfield | Gm-csf inhibiting oligopeptides |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
US6309636B1 (en) | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
BR9609743A (pt) | 1995-07-27 | 1999-03-02 | Genentech Inc | Formulação reconstituída estável método para a preparação de uma formulação artigo manufaturado e uso da formação |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
WO1999054440A1 (en) | 1998-04-21 | 1999-10-28 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
BR0108499A (pt) | 2000-02-14 | 2003-03-11 | Mitsubishi Pharma Corp | Agente terapêutico para hepatite c |
US20050271663A1 (en) | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
MXPA04000747A (es) | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
ES2392073T3 (es) | 2001-11-08 | 2012-12-04 | Abbott Biotherapeutics Corp. | Formulación farmacéutica líquida estable de anticuerpos IGG |
ATE509032T1 (de) | 2002-02-13 | 2011-05-15 | Ludwig Inst For Cancer Res Ltd | Chimerizierte gm-csf antikörper |
DE60322513D1 (de) | 2002-02-27 | 2008-09-11 | Immunex Corp | Stabilisierte TNFR-Fc Formulierung mit Arginin |
US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
CN101824088B (zh) | 2002-10-30 | 2012-05-30 | 健泰科生物技术公司 | Il-17产生的抑制 |
CA2562771C (en) | 2004-04-12 | 2013-04-09 | Medimmune, Inc. | Anti-il-9 antibody formulations and uses thereof |
EP1593690B1 (en) | 2004-05-05 | 2009-07-01 | Micromet AG | Preparation of ScFv antibody fragments |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
KR20070095949A (ko) | 2004-12-16 | 2007-10-01 | 제넨테크, 인크. | 자가면역 장애의 치료 방법 |
GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
RU2458071C2 (ru) | 2005-04-18 | 2012-08-10 | Микромет Аг | Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека |
HUE058876T2 (hu) | 2005-05-18 | 2022-09-28 | Morphosys Ag | Anti-GM-CSF antitestek és felhasználásuk |
JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトgm−csfに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
JP2009525986A (ja) | 2006-02-03 | 2009-07-16 | メディミューン,エルエルシー | タンパク質製剤 |
CN101501070B (zh) | 2006-02-08 | 2013-12-25 | 诺福泰克公司 | 抗原性gm-csf肽和针对gm-csf的抗体 |
DK2423229T3 (da) | 2006-03-27 | 2013-08-05 | Medimmune Ltd | Bindingselement til GM-CSF-receptor |
MX2009005398A (es) * | 2006-11-21 | 2009-08-20 | Kalobios Pharmaceuticals Inc | Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf. |
JP5513380B2 (ja) | 2007-06-25 | 2014-06-04 | アムジエン・インコーポレーテツド | 肝細胞増殖因子に対する特異的結合剤の組成物 |
TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
MX2010005291A (es) | 2007-11-13 | 2010-11-12 | Evec Inc | Anticuerpos monoclonales que se unen a hgm-csf y composiciones medicas que comprenden los mismos. |
CN102037016B (zh) | 2008-04-28 | 2015-06-03 | 卡罗拜奥斯制药公司 | 针对粒细胞巨噬细胞集落刺激因子的抗体 |
EA024654B1 (ru) | 2008-04-29 | 2016-10-31 | Эмджен Рисерч (Мьюник) Гмбх | Ингибиторы гранулоцитарно-макрофагального колониестимулирующего фактора (gm-csf) и интерлейкина-17 (il-17) для терапии |
EP3381471B1 (en) | 2008-12-22 | 2024-03-20 | The University of Melbourne | Pain treatment |
KR20140064943A (ko) | 2009-05-05 | 2014-05-28 | 모르포시스 아게 | 다발성 경화증의 치료 |
EP2458990B1 (en) | 2009-07-28 | 2016-03-30 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
CA2783715A1 (en) | 2009-12-29 | 2011-07-07 | F. Hoffmann-La Roche Ag | Novel antibody formulation |
CN107496917B (zh) | 2010-02-26 | 2021-06-11 | 诺沃—诺迪斯克有限公司 | 包含稳定抗体的组合物 |
EP2399604A1 (en) | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
US20140335081A1 (en) | 2011-10-10 | 2014-11-13 | Medlmmune Limited | Treatment For Rheumatoid Arthritis |
KR20240091288A (ko) | 2012-09-20 | 2024-06-21 | 모르포시스 아게 | 류마티스 관절염에 대한 치료 |
AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res (Munich) Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
EP2914289B1 (en) * | 2012-10-31 | 2019-05-22 | Takeda GmbH | Lyophilized formulation comprising gm-csf neutralizing compound |
JP6346389B1 (ja) | 2016-08-03 | 2018-06-20 | 古河電気工業株式会社 | 金属粒子含有組成物 |
-
2014
- 2014-09-01 CN CN202410511905.9A patent/CN118178647A/zh active Pending
- 2014-09-01 MX MX2016002177A patent/MX2016002177A/es unknown
- 2014-09-01 AU AU2014314053A patent/AU2014314053C1/en active Active
- 2014-09-01 RU RU2016109944A patent/RU2714919C2/ru active
- 2014-09-01 WO PCT/EP2014/068489 patent/WO2015028657A1/en active Application Filing
- 2014-09-01 BR BR112016003293A patent/BR112016003293A8/pt not_active Application Discontinuation
- 2014-09-01 JP JP2016537322A patent/JP2016536327A/ja active Pending
- 2014-09-01 CA CA2922251A patent/CA2922251C/en active Active
- 2014-09-01 CN CN201480047403.XA patent/CN105705518A/zh active Pending
- 2014-09-01 KR KR1020227010431A patent/KR20220045064A/ko not_active IP Right Cessation
- 2014-09-01 ES ES14758384T patent/ES2860480T3/es active Active
- 2014-09-01 EP EP21161450.8A patent/EP3889178A1/en active Pending
- 2014-09-01 US US14/913,578 patent/US10745475B2/en active Active
- 2014-09-01 KR KR1020167007575A patent/KR20160044035A/ko not_active IP Right Cessation
- 2014-09-01 EP EP14758384.3A patent/EP3039039B1/en active Active
- 2014-09-01 KR KR1020247017478A patent/KR20240090993A/ko active Search and Examination
-
2016
- 2016-02-18 MX MX2021010472A patent/MX2021010472A/es unknown
-
2020
- 2020-03-11 JP JP2020042267A patent/JP2020109108A/ja active Pending
- 2020-06-12 AU AU2020203917A patent/AU2020203917A1/en not_active Abandoned
- 2020-08-17 US US16/995,617 patent/US11795216B2/en active Active
-
2022
- 2022-05-02 JP JP2022076303A patent/JP2022105160A/ja active Pending
-
2023
- 2023-08-04 AU AU2023210647A patent/AU2023210647A1/en active Pending
-
2024
- 2024-06-27 JP JP2024103720A patent/JP2024123249A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2023210647A1 (en) | 2023-10-12 |
CA2922251C (en) | 2023-10-17 |
JP2016536327A (ja) | 2016-11-24 |
CN118178647A (zh) | 2024-06-14 |
US20210171620A1 (en) | 2021-06-10 |
KR20160044035A (ko) | 2016-04-22 |
EP3889178A1 (en) | 2021-10-06 |
AU2014314053B2 (en) | 2020-03-12 |
MX2021010472A (es) | 2021-10-01 |
JP2024123249A (ja) | 2024-09-10 |
US20160355584A1 (en) | 2016-12-08 |
RU2714919C2 (ru) | 2020-02-21 |
JP2020109108A (ja) | 2020-07-16 |
EP3039039B1 (en) | 2021-03-10 |
EP3039039A1 (en) | 2016-07-06 |
WO2015028657A1 (en) | 2015-03-05 |
BR112016003293A8 (pt) | 2022-08-16 |
US10745475B2 (en) | 2020-08-18 |
MX2016002177A (es) | 2016-06-28 |
RU2016109944A (ru) | 2017-10-06 |
AU2014314053C1 (en) | 2023-11-02 |
AU2014314053A1 (en) | 2016-02-11 |
ES2860480T3 (es) | 2021-10-05 |
CN105705518A (zh) | 2016-06-22 |
RU2016109944A3 (pt) | 2018-07-09 |
JP2022105160A (ja) | 2022-07-12 |
KR20220045064A (ko) | 2022-04-12 |
US11795216B2 (en) | 2023-10-24 |
CA2922251A1 (en) | 2015-03-05 |
KR20240090993A (ko) | 2024-06-21 |
AU2020203917A1 (en) | 2020-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016003293A2 (pt) | anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos | |
BR112018010464A2 (pt) | formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas | |
MX2021008113A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
BR112015015891A8 (pt) | Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica | |
BR112015022597A2 (pt) | partículas modificadoras da imunidade para o tratamento de inflamação | |
PH12015502553A1 (en) | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof | |
BR112017000664A2 (pt) | anticorpo anti-pd-1 e seu uso | |
BR112016025048A2 (pt) | compostos e composições como agonistas do receptor tipo toll7 | |
EA201690881A1 (ru) | Соединения-ингибиторы аутотаксина | |
BR112017023374A2 (pt) | formulação de anticorpo anti-cgrp | |
BR112016019176A2 (pt) | anticorpos il-21 | |
BR112017008945A2 (pt) | Anticorpos anti-cs1 e conjugados fármaco- anticorpo | |
TN2016000057A1 (en) | Methods of treating sporadic inclusion body myositis | |
MX2019015738A (es) | Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos. | |
BR112016003201A2 (pt) | inibidores de grp94 seletivos e usos dos mesmos | |
EA201400625A1 (ru) | Антитела против pd-l1 и их применение | |
MX2020011993A (es) | Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide. | |
BR112012005957A2 (pt) | compostos tricíclicos e usos farmacêuticos dos mesmos | |
BR112017008045A2 (pt) | compostos como inibidores de nik | |
BR112014002817A2 (pt) | Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62 | |
BR112017005209A2 (pt) | compostos moduladores de pirrolopiridina substituída por metila e trifluorometila de rorc2 e seu uso | |
MX2015009045A (es) | Composiciones y metodos para tratar el dolor severo. | |
MX2014013678A (es) | Agentes para neutralizacion de influenza. | |
BR112017003332A2 (pt) | uso de antagonistas de il-17 para inibir a progressão de dano estrutural em pacientes com artrite psoriásica | |
NI201600070A (es) | Inhibidores tetracíclicos de autotaxina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |